Home LiteratureArticle Details
PMID: 3102631 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.

The Journal of infectious diseases ·Vol. 155 ·No. 4 ·1987-04-00 ·Pages 783-8

Johnson M, Miniter P, Andriole VT

Abstract

Ciprofloxacin, azlocillin, and tobramycin, used alone and in combination, were studied in a model of lethal pseudomonas sepsis in rats. Ciprofloxacin alone at all doses studied and tobramycin alone at the highest dose reduced mortality significantly compared with saline controls. In contrast, survival was not improved with either azlocillin alone at all doses studied or lower doses of tobramycin alone. The combination of ciprofloxacin and azlocillin was synergistic in rats with systemic pseudomonas infection. Ciprofloxacin was rapidly absorbed, and effective levels persisted for 1-4 hr relative to the dose administered. These data suggest that ciprofloxacin may be a potent agent, either alone or in combination with azlocillin, in the treatment of severe pseudomonas infections.

MeSH Terms
Animals Azlocillin/pharmacology,therapeutic use Ciprofloxacin/pharmacology,therapeutic use Drug Synergism Drug Therapy, Combination Female Pseudomonas Infections/drug therapy Pseudomonas aeruginosa/drug effects Rats Rats, Inbred Strains Tobramycin/pharmacology,therapeutic use
Chemicals
Ciprofloxacin Azlocillin Tobramycin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Johnson M
Miniter P
Andriole V T
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
Published
1987-04-00
Pages
783-8
Language
English
Region
United States
NLM ID
0413675
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com